BRPI0518080A - bactéria transformada ou uma progênie da mesma, método para transformar uma bactéria, mycobacterium transformada ou uma progênie da mesma e vacina compreendendo uma mycobacterium transformada ou uma progênie da mesma - Google Patents

bactéria transformada ou uma progênie da mesma, método para transformar uma bactéria, mycobacterium transformada ou uma progênie da mesma e vacina compreendendo uma mycobacterium transformada ou uma progênie da mesma

Info

Publication number
BRPI0518080A
BRPI0518080A BRPI0518080-5A BRPI0518080A BRPI0518080A BR PI0518080 A BRPI0518080 A BR PI0518080A BR PI0518080 A BRPI0518080 A BR PI0518080A BR PI0518080 A BRPI0518080 A BR PI0518080A
Authority
BR
Brazil
Prior art keywords
progeny
transformed
mycobacterium
bacterium
vaccine
Prior art date
Application number
BRPI0518080-5A
Other languages
English (en)
Inventor
Ronggai Sun
David Michael Hone
Jerald C Sadoff
Original Assignee
Aeras Global Tb Vaccine Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeras Global Tb Vaccine Found filed Critical Aeras Global Tb Vaccine Found
Publication of BRPI0518080A publication Critical patent/BRPI0518080A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

BACTéRIA TRANSFORMADA OU UMA PROGêNIE DA MESMA, MéTODO PARA TRANSFORMAR UMA BACTéRIA, MYCOBACTERIUM TRANSFORMADA OU UMA PROGêNIE DA MESMA E VACINA COMPREENDENDO UMA MYCOBACTERIUM TRANSFORMADA OU UMA PROGêNIE DA MESMA. As estirpes recombinantes de Mycobacterium com propriedades de vacina melhoradas para o uso como alguns agentes de vacinas são proporcionadas. As estirpes parentas das estirpes recombinantes de Mycobacterium são selecionadas por causa da sua potente imuno-genicidade. As estirpes de Mycobacterium não exibem resistência antibiótica e não exibem uma transferência horizontal para bactérias de gram-negativo.
BRPI0518080-5A 2004-12-01 2005-11-29 bactéria transformada ou uma progênie da mesma, método para transformar uma bactéria, mycobacterium transformada ou uma progênie da mesma e vacina compreendendo uma mycobacterium transformada ou uma progênie da mesma BRPI0518080A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63197704P 2004-12-01 2004-12-01
PCT/US2005/042976 WO2006060332A2 (en) 2004-12-01 2005-11-29 Electroporation of mycobacterium and overexpression of antigens in mycobacteria

Publications (1)

Publication Number Publication Date
BRPI0518080A true BRPI0518080A (pt) 2008-10-28

Family

ID=36565595

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518080-5A BRPI0518080A (pt) 2004-12-01 2005-11-29 bactéria transformada ou uma progênie da mesma, método para transformar uma bactéria, mycobacterium transformada ou uma progênie da mesma e vacina compreendendo uma mycobacterium transformada ou uma progênie da mesma

Country Status (16)

Country Link
US (1) US7625572B2 (pt)
EP (1) EP1817061B1 (pt)
JP (1) JP5461776B2 (pt)
KR (1) KR101382215B1 (pt)
CN (1) CN101076356B (pt)
AP (1) AP2869A (pt)
AT (1) ATE517637T1 (pt)
AU (1) AU2005312062B2 (pt)
BR (1) BRPI0518080A (pt)
CA (1) CA2587507C (pt)
DK (1) DK1817061T3 (pt)
EA (1) EA012182B1 (pt)
ES (1) ES2370885T3 (pt)
MX (1) MX2007006552A (pt)
WO (1) WO2006060332A2 (pt)
ZA (1) ZA200704764B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198358B (zh) 2004-12-01 2013-06-26 Aeras全球Tb疫苗基金会 具有增强的逃出内体能力的重组bcg菌株
US7829104B2 (en) * 2004-12-01 2010-11-09 Aeras Global Tb Vaccine Foundation Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
US8852916B2 (en) * 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
WO2007079351A2 (en) * 2005-12-15 2007-07-12 Aeras Global Tb Vaccine Foundation Novel prime-boost combinations of attenuated mycobacterium
WO2009045575A2 (en) * 2007-06-14 2009-04-09 The Regents Of The University Of California Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins
EP2834356A4 (en) * 2012-04-02 2015-09-02 Univ Arizona RECOMBINANT BACTERIUM FOR INDUCING A CELLULAR IMMUNE RESPONSE
IN2014DN08675A (pt) 2012-04-16 2015-05-22 Aeras Global Tb Vaccine Found
US11712777B2 (en) * 2019-06-10 2023-08-01 Rohm And Haas Electronic Materials Cmp Holdings, Inc. Cationic fluoropolymer composite polishing pad
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN118221791B (zh) * 2024-05-23 2024-08-23 山东第二医科大学 一种Rv0653c蛋白、其抗体及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736367A (en) 1992-03-31 1998-04-07 Medimmune, Inc. Vectors and prokaryotes which autocatalytically delete antibiotic resistance
US5783386A (en) * 1994-02-24 1998-07-21 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Mycobacteria virulence factors and a novel method for their identification
CN1136280A (zh) * 1994-07-29 1996-11-20 味之素株式会社 抗艾滋病分泌型重组bcg疫苗
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
US6562348B2 (en) * 1999-07-08 2003-05-13 Albert Einstein College Of Medicine Of Yeshiva University Recombinant M. tuberculosis auxotrophic for leucine and vaccines using same
US6423545B1 (en) * 1999-07-08 2002-07-23 Albert Einstein College Of Medicine Of Yeshiva University Unmarked deletion mutants of mycobacteria and methods of using same
CN1342771A (zh) * 2001-09-17 2002-04-03 复旦大学 结核分枝杆菌Ag85B抗原的表达纯化和作为疫苗组份的应用
AP2007004059A0 (en) * 2005-01-05 2007-08-31 Isis Innovation Compositions for immunizing against mycobacterium

Also Published As

Publication number Publication date
AP2007004021A0 (en) 2007-06-30
ATE517637T1 (de) 2011-08-15
DK1817061T3 (da) 2011-11-14
WO2006060332A3 (en) 2006-08-03
AP2869A (en) 2014-03-31
WO2006060332A2 (en) 2006-06-08
EP1817061A4 (en) 2009-07-08
EP1817061B1 (en) 2011-07-27
ZA200704764B (en) 2008-09-25
JP5461776B2 (ja) 2014-04-02
CN101076356A (zh) 2007-11-21
EP1817061A2 (en) 2007-08-15
US7625572B2 (en) 2009-12-01
MX2007006552A (es) 2007-08-20
EA200701130A1 (ru) 2007-12-28
CN101076356B (zh) 2013-04-03
AU2005312062B2 (en) 2011-11-17
KR20070111452A (ko) 2007-11-21
AU2005312062A1 (en) 2006-06-08
ES2370885T3 (es) 2011-12-23
EA012182B1 (ru) 2009-08-28
CA2587507C (en) 2013-11-19
US20060121054A1 (en) 2006-06-08
CA2587507A1 (en) 2006-06-08
KR101382215B1 (ko) 2014-04-08
JP2008521435A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
BRPI0518080A (pt) bactéria transformada ou uma progênie da mesma, método para transformar uma bactéria, mycobacterium transformada ou uma progênie da mesma e vacina compreendendo uma mycobacterium transformada ou uma progênie da mesma
CY1123299T1 (el) Ανοσοενισχυτικη μηνιγκιτιδοκοκκικη πρωτεϊνη προσδεσης παραγοντα η
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
CY1119753T1 (el) Λυσινικη αλφα αζτρεοναμη
BRPI0417825A (pt) métodos para uso de lactobacilli probióticos para animais de estimação
BR0301038A (pt) Bandagem não pneumática elástica
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
CY1111739T1 (el) Πυριδινο[3,4-β]πυραζινονες
NZ593220A (en) Immunostimulatory oligonucleotides
IL204732A (en) @@@@@ - Diplooro - @@ - Deoxy @ tetrahydro uridines, preparations containing them and their use in making @ drugs
BRPI0702762B8 (pt) mecanismo de fixação de cassete
CL2008000751A1 (es) Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c.
DK1624762T3 (da) Probiotisk præparat med mindst to mælkesyrebakteriestammer som er i stand til kolonisere mavetarmkanalen, i kombination med at de besidder overlevelsesegenskab, tarmbindende egenskab, en infektionsbeskyttelsesegenskab og en fiberfermenterende egenskab
UY26783A1 (es) Antígenos de estreptococo.
DE602004021644D1 (de) Gyraseinhibitoren und deren verwendungen
NO20073088L (no) Deacylering av LPS i gramnegative bakterier
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
CR11259A (es) Bromhidrato de bupropion y aplicaciones terapueticas
AR068419A1 (es) Cepas de mycoplasma atenuadas vivas
BRPI0417192A (pt) composição imunoestimulante, compreendendo pelo menos um agonista dos receptores toll-like 7 ou do receptor toll-like 8 e um agonista do receptor toll-like 4
HRP20201021T1 (hr) Modificirane stanice domaćini i njihova upotreba
AR054937A1 (es) Goma de mascar biodegradable
MX2012004622A (es) Adyuvante para vacunas, vacunas que lo comprenden y usos.
SV2006002290A (es) Nonadepsipeptidos acilados ii ref. bhc041327-sv

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL